COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population

被引:123
作者
Fletcher, Monica J. [1 ]
Upton, Jane [1 ]
Taylor-Fishwick, Judith
Buist, Sonia A. [2 ]
Jenkins, Christine [3 ]
Hutton, John [4 ]
Barnes, Neil [5 ]
Van der Molen, Thys [6 ]
Walsh, John W.
Jones, Paul [7 ]
Walker, Samantha [1 ]
机构
[1] Educ Hlth, Warwick, England
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Woolcock Inst Med Res, Sydney, NSW, Australia
[4] York Hlth Econ Consortium, York, N Yorkshire, England
[5] London Chest Hosp, Med & Emergency Directorate, London, England
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands
[7] St Georges Univ London, London, England
关键词
GLOBAL BURDEN; RISK-FACTORS; PREVALENCE; DISABILITY; COMORBIDITIES; EPIDEMIOLOGY; ECONOMICS; SYMPTOMS; SMOKING; COST;
D O I
10.1186/1471-2458-11-612
中图分类号
R1 [预防医学、卫生学];
学科分类号
100235 [预防医学];
摘要
Background: Approximately 210 million people are estimated to have chronic obstructive pulmonary disease [COPD] worldwide. The burden of disease is known to be high, though less is known about those of a younger age. The aim of this study was to investigate the wider personal, economic and societal burden of COPD on a cross country working-age cohort. Methods: A cross-country [Brazil, China, Germany, Turkey, US, UK] cross-sectional survey methodology was utilised to answer the research questions. 2426 participants aged 45-67 recruited via a number of recruitment methods specific to each country completed the full survey. Inclusion criteria were a recalled physician diagnosis of COPD, a smoking history of > 10 pack years and the use of COPD medications in the previous 3 months prior to questioning. The survey included items from the validated Work Productivity and Activity Impairment [WPAI] scale and the EuroQoL 5 Dimension [EQ-5D] scale. Disease severity was measured using the 5-point MRC [Medical Research Council] dyspnoea scale as a surrogate measure. Results: 64% had either moderate [n = 1012] or severe [n = 521] COPD, although this varied by country. 75% of the cohort reported at least one comorbid condition. Quality of life declined with severity of illness [mild, mean EQ-5D score = 0.84; moderate 0.58; severe 0.41]. The annual cost of healthcare utilisation [excluding treatment costs and diagnostic tests] per individual was estimated to be $2,364 [1,500] pound. For those remaining in active employment [n: 677]: lost time from work cost the individual an average of $880 [556] pound per annum and lifetime losses of $7,365 [4,661] pound amounting to $596,000 [377,000] pound for the cohort. 447 [similar to 40%] of the working population had retired prematurely because of COPD incurring individual estimated lifetime income losses of $316,000 [200,000] pound or a combined total of $141 m [89.6 pound m]. As the mean age of retirees was 58.3 and average time since retirement was 4 years, this suggests the average age of retirement is around 54. This would mean a high societal and economic impact in all study countries, particularly where typical state retirement ages are higher, for example in Brazil, Germany and the UK [65] and the US [65,66,67], compared to Turkey [58 for women, 60 for men] and China [60]. Conclusions: Although generalisation across a broader COPD population is limited due to the varied participant recruitment methods, these data nevertheless suggest that COPD has significant personal, economic and societal burden on working age people. Further efforts to improve COPD diagnosis and management are required.
引用
收藏
页数:13
相关论文
共 52 条
[1]
[Anonymous], 2007, Global surveillance
[2]
[Anonymous], 2009, Unit Costs of Health and Social Care 2009
[3]
[Anonymous], CCEMG-EPPI-Centre Cost Converter
[4]
EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY [J].
ANTHONISEN, NR ;
CONNETT, JE ;
KILEY, JP ;
ALTOSE, MD ;
BAILEY, WC ;
BUIST, AS ;
CONWAY, WA ;
ENRIGHT, PL ;
KANNER, RE ;
OHARA, P ;
OWENS, GR ;
SCANLON, PD ;
TASHKIN, DP ;
WISE, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19) :1497-1505
[5]
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease [J].
Bestall, JC ;
Paul, EA ;
Garrod, R ;
Garnham, R ;
Jones, PW ;
Wedzicha, JA .
THORAX, 1999, 54 (07) :581-586
[6]
The cost of treating patients with COPD in Denmark - A population study of COPD patients compared with non-COPD controls [J].
Bilde, Lone ;
Rud Svenning, Anders ;
Dollerup, Jens ;
Baekke Borgeskov, Hanne ;
Lange, Peter .
RESPIRATORY MEDICINE, 2007, 101 (03) :539-546
[7]
Britton M, 2003, RESPIRMED SC, V97, pS71
[8]
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients [J].
Brown, RE ;
Hutton, J .
ANTI-CANCER DRUGS, 1998, 9 (10) :899-907
[9]
International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study [J].
Buist, A. Sonia ;
McBurnie, Mary Ann ;
Vollmer, William M. ;
Gillespie, Suzanne ;
Burney, Peter ;
Mannino, David M. ;
Menezes, Ana M. B. ;
Sullivan, Sean D. ;
Lee, Todd A. ;
Weiss, Kevin B. ;
Jensen, Robert L. ;
Marks, Guy B. ;
Gulsvik, Amund ;
Nizankowska-Mogilnicka, Ewa .
LANCET, 2007, 370 (9589) :741-750